Edgewise Therapeutics, Inc. has shared long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy. Sevasemten is an orally administered small molecule inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. MESA is an open-label extension evaluating sevasemten long-term safety, tolerability, and efficacy in adults and adolescents with Becker previously treated in sevasemten clinical trials (including ARCH, CANYON/GRAND CANYON, and DUNE studies).

The data show participants on sevasemten maintained long-term function, with North Star Ambulatory Assessment (NSAA) functional scores of ARCH and CANYON trial participants treated with sevasemten remaining consistent after 3.5 years and 2 years, respectively. Additionally, in MESA, Edgewise also reported that these NSAA scores observed in the sevasemten treatment arm diverged from predicted natural history declines.

According to Edgewise, the company expects to announce top-line results of the sevasemten placebo-controlled pivotal cohort, GRAND CANYON, in Q4 2026. If positive, Edgewise intends to advance towards a marketing application.

Read Edgewise’s press release here.